Mano Mino

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression.

A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: August 30, 2026

Concurrent tumor lysis syndrome and 5-fluorouracil encephalopathy during the first cycle of zolbetuximab plus mFOLFOX6 for CLDN18.2-positive gastric cancer: a case report.

Concurrent tumor lysis syndrome and 5-fluorouracil encephalopathy during the first cycle of zolbetuximab plus mFOLFOX6 for CLDN18.2-positive gastric cancer: a case report.

Journal: International cancer conference journal

Published: July 07, 2025

Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell Lymphoma.

Site- and Stage-Adapted Treatment Strategies for Gastrointestinal Diffuse Large B-Cell Lymphoma.

Journal: European journal of haematology

Published: April 10, 2025

Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy.

Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: June 26, 2024

Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant

Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 06, 2023

Hemoglobin-platelet index as a prognostic factor in patients with peripheral T-cell lymphoma.

Hemoglobin-platelet index as a prognostic factor in patients with peripheral T-cell lymphoma.

Journal: EJHaem

Published: February 17, 2023

Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.

Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.

Journal: Annals of hematology

Published: February 11, 2023

Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience

Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: November 09, 2022

Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.

Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.

Journal: Cancer medicine

Published: September 07, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026